Novavax Inc. closed 68.32% below its 52-week high of $23.86, which the company achieved on June 6th.

Vaccine makers Moderna Inc (NASDAQ:MRNA) and Novavax Inc (NASDAQ:NVAX) are facing selling pressure on Wednesday following reports suggesting the Trump administration will end support for Gavi.

Shares of Novavax Inc. NVAX rose 1.18% to $7.69 Monday, on what proved to be an all-around great trading session for the ...

Novavax reached a settlement with Gavi, the Vaccine Alliance, after t | International vaccine partnership Gavi has ...

As it returns from the brink, the vaccine developer has brought in Dr. Ruxandra Draghia-Akli — and her industry and public health chops — to lead R&D.

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Novavax, Inc. (Nasdaq: NVAX) today announced that James Young, PhD, is retiring as Chair of the Board and Margaret McGlynn, RPh, has been appointed as his successor. The Company also appointed ...

The U.S. is planning to end its financial support for Gavi, a WHO-backed organization that aims to ensure equitable access to vaccines worldwide, The New York Times reported Wednesday, citing a memo ...

The Trump administration’s decision to cut funding for Gavi, as part of a broader reduction in foreign aid, may have ...

Tilray Brands' results have not been good, nor has the state of the cannabis market. Novavax failed in the COVID-19 space, ...

Novavax, Inc. (NASDAQ:NVAX – Get Free Report) has earned an average recommendation of “Hold” from the seven brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst ...

In the closing of the recent trading day, Novavax (NVAX) stood at $7.91, denoting a -0.57% change from the preceding trading day. Recently, Zacks.com users have been paying close attention to Novavax ...